生物来源
rabbit
质量水平
抗体形式
affinity purified immunoglobulin
抗体产品类型
primary antibodies
克隆
polyclonal
纯化方式
affinity chromatography
种属反应性
rhesus macaque, horse, human
种属反应性(根据同源性预测)
rat (based on 100% sequence homology), mouse (based on 100% sequence homology), hamster (based on 100% sequence homology), cat (based on 100% sequence homology), equine (based on 100% sequence homology), canine (based on 100% sequence homology), chimpanzee (based on 100% sequence homology), rhesus monkey (based on 100% sequence homology)
技术
dot blot: suitable
immunocytochemistry: suitable
immunohistochemistry: suitable
NCBI登记号
UniProt登记号
运输
wet ice
靶向翻译后修饰
phosphorylation (pSer3291)
基因信息
human ... BRCA2(675)
相关类别
一般描述
BRCA2 (乳腺癌2型易感蛋白)是一种由BRCA2基因编码的肿瘤抑制蛋白(tumor suppressor protein )。
该基因编码的蛋白在无错式双链断裂修复(error-free double-strand break repair)和同源重组中起直接作用。BRCA2 类似于肿瘤抑制基因BRCA1。BRCA2以及BRCA1 的遗传突变与增加的乳腺或卵巢癌患病风险有关。尽管RCA1 和BRCA2基因的结构差别很大,它们有一些类似的功能。两种基因产生的蛋白对受损DNA的修复必不可少,并且与RAD51基因产生的蛋白相互作用。这三种蛋白一起在维持人类基因组的稳定性方面起一定作用,并且防止出现可导致癌症的危险基因重排。
该基因编码的蛋白在无错式双链断裂修复(error-free double-strand break repair)和同源重组中起直接作用。BRCA2 类似于肿瘤抑制基因BRCA1。BRCA2以及BRCA1 的遗传突变与增加的乳腺或卵巢癌患病风险有关。尽管RCA1 和BRCA2基因的结构差别很大,它们有一些类似的功能。两种基因产生的蛋白对受损DNA的修复必不可少,并且与RAD51基因产生的蛋白相互作用。这三种蛋白一起在维持人类基因组的稳定性方面起一定作用,并且防止出现可导致癌症的危险基因重排。
约390 kDa
免疫原
KLH 偶联的线性肽,对应于Ser3291周围内部结构域上及其周围磷酸化的人 BRCA2。
表位:Ser3291周围的内部结构域
应用
免疫细胞化学分析: 一个先前批次的1:500稀释液在MCF-7细胞中检测到BRCA2。
免疫组化分析: 一个先前批次的1:100稀释液在转移性导管癌组织中检测到BRCA2。
免疫组化分析: 一个先前批次的1:100稀释液在转移性导管癌组织中检测到BRCA2。
抗磷酸化BRCA2(Ser3291)抗体是一种兔多克隆抗体,可用于检测磷酸化BRCA2(Ser3291),也称含BRCA1/BRCA2复合物亚基2&范科尼贫血组D1蛋白3, 已在 ICC、IHC、DB中进行了验证。
研究子类别
细胞周期,DNA 复制&修复
肿瘤蛋白
细胞周期,DNA 复制&修复
肿瘤蛋白
生化/生理作用
该抗体识别Ser3291周围内部结构域上及其周围的磷酸化人 BRCA2。
分析说明
对照
磷酸化和非磷酸化BRCA2的修饰和未修饰肽
磷酸化和非磷酸化BRCA2的修饰和未修饰肽
通过斑点印迹法对磷酸化和非磷酸化BRCA2的修饰和未修饰肽进行评估。
斑点印迹分析: 2 µg/mL该抗体在磷酸化和非磷酸化BRCA2的修饰和未修饰肽中检测到BRCA2。
斑点印迹分析: 2 µg/mL该抗体在磷酸化和非磷酸化BRCA2的修饰和未修饰肽中检测到BRCA2。
其他说明
浓度:请参考批次特异性浓缩物的检验报告。
未找到合适的产品?
试试我们的产品选型工具.
储存分类代码
12 - Non Combustible Liquids
WGK
WGK 1
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Lifeng Chen et al.
Clinical and translational medicine, 11(3), e341-e341 (2021-03-31)
PARP inhibitors induce DNA lesions, the repair of which are highly dependent on homologous recombination (HR), and preferentially kill HR- deficient cancers. However, cancer cells have developed several mechanisms to transform HR and confer drug resistance to PARP inhibition. Therefore
Gro Elise Rødland et al.
Frontiers in oncology, 9, 1301-1301 (2019-12-19)
The CD37 targeting radioimmunoconjugate 177Lu-lilotomab satetraxetan (Betalutin) is currently being evaluated in a clinical phase 2b trial for patients with follicular lymphoma (FL) and in a phase 1 trial for patients with diffuse large B-cell lymphoma (DLBCL). Herein we have
Sissel Hauge et al.
Oncotarget, 8(7), 10966-10979 (2016-12-29)
Recent studies have shown synergistic cytotoxic effects of simultaneous Chk1- and Wee1-inhibition. However, the mechanisms behind this synergy are not known. Here, we present a flow cytometry-based screen for compounds that cause increased DNA damage in S-phase when combined with
Grete Hasvold et al.
Molecular oncology, 10(5), 764-773 (2016-01-23)
Hypoxia promotes an aggressive tumor phenotype with increased genomic instability, partially due to downregulation of DNA repair pathways. However, genome stability is also surveilled by cell cycle checkpoints. An important issue is therefore whether hypoxia also can influence the DNA
Gro Elise Rødland et al.
Cancers, 13(15) (2021-08-08)
Inhibitors of WEE1 and ATR kinases are considered promising for cancer treatment, either as monotherapy or in combination with chemo- or radiotherapy. Here, we addressed whether simultaneous inhibition of WEE1 and ATR might be advantageous. Effects of the WEE1 inhibitor
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持